Advances and future challenges in adenoviral vector pharmacology and targeting.
about
New viruses for cancer therapy: meeting clinical needsDevelopment of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5-based ConstructsDevelopment of a generic adenovirus delivery system based on structure-guided design of bispecific trimeric DARPin adaptersMEN1 gene replacement therapy reduces proliferation rates in a mouse model of pituitary adenomas.Peptide-based technologies to alter adenoviral vector tropism: ways and means for systemic treatment of cancerCombining Oncolytic Virotherapy with p53 Tumor Suppressor Gene TherapyDevelopment of Sendai virus vectors and their potential applications in gene therapy and regenerative medicine.Molecular characterization of a lizard adenovirus reveals the first atadenovirus with two fiber genes and the first adenovirus with either one short or three long fibers per pentonDevelopment of peritoneal tumor-targeting vector by in vivo screening with a random peptide-displaying adenovirus library.Mutation of the fiber shaft heparan sulphate binding site of a 5/3 chimeric adenovirus reduces liver tropism.Combinatorial targeting of 2 different steps in adenoviral DNA replication by herpes simplex virus thymidine kinase and artificial microRNA expression for the inhibition of virus multiplication in the presence of ganciclovirAmplified and persistent immune responses generated by single-cycle replicating adenovirus vaccines.Mutation in fiber of adenovirus serotype 5 gene therapy vector decreases liver tropism.Transcriptional targeting of primary and metastatic tumor neovasculature by an adenoviral type 5 roundabout4 vector in miceIL-1α and complement cooperate in triggering local neutrophilic inflammation in response to adenovirus and eliminating virus-containing cellsSynthetic tumor networks for screening drug delivery systemsAd5/48 hexon oncolytic virus expressing sTGFβRIIFc produces reduced hepatic and systemic toxicities and inhibits prostate cancer bone metastases.A Genetically Modified Adenoviral Vector with a Phage Display-Derived Peptide Incorporated into Fiber Fibritin Chimera Prolongs Survival in Experimental Glioma.Mucosal vaccination by adenoviruses displaying reovirus sigma 1.Identification of adenovirus serotype 5 hexon regions that interact with scavenger receptors.Evaluation of polymer shielding for adenovirus serotype 6 (Ad6) for systemic virotherapy against human prostate cancers.Retargeted oncolytic adenovirus displaying a single variable domain of camelid heavy-chain-only antibody in a fiber protein.SR-A and SREC-I are Kupffer and endothelial cell receptors for helper-dependent adenoviral vectors.Circulating antibodies and macrophages as modulators of adenovirus pharmacologyIn vivo, cardiac-specific knockdown of a target protein, malic enzyme-1, in rat via adenoviral delivery of DNA for non-native miRNA.Prokineticin receptor-1 is a new regulator of endothelial insulin uptake and capillary formation to control insulin sensitivity and cardiovascular and kidney functions.Adenovirus: the first effective in vivo gene delivery vectorModeling pre-existing immunity to adenovirus in rodents: immunological requirements for successful development of a recombinant adenovirus serotype 5-based ebola vaccine.Transgene Expression and Host Cell Responses to Replication-Defective, Single-Cycle, and Replication-Competent Adenovirus Vectors.Innate immunity to adenovirus.CD46-mediated transduction of a species D adenovirus vaccine improves mucosal vaccine efficacy.Genetic approaches to investigate the role of CREB in neuronal plasticity and memory.CD40-targeted adenoviral cancer vaccines: the long and winding road to the clinic.Recent advances in developing nucleic acid-based HBV therapy.Adenovirus-triggered innate signalling pathways.Sorting Out Pandora's Box: Discerning the Dynamic Roles of Liver Microenvironment in Oncolytic Virus Therapy for Hepatocellular Carcinoma.Adenoviruses as gene/vaccine delivery vectors: promises and pitfalls.Small-size recombinant adenoviral hexon protein fragments for the production of virus-type specific antibodies.Antitumor Efficacy of SLPI Promoter-Controlled Expression of Artificial microRNA Targeting EGFR in a Squamous Cell Carcinoma Cell Line.Single-step concentration and purification of adenoviruses by coxsackievirus-adenovirus receptor-binding capture and elastin-like polypeptide-mediated precipitation.
P2860
Q24567699-9AC1D0D9-0334-4813-A905-CF2E894A96D9Q26782083-5D35BA9F-11B9-479F-B6D5-8F48825B69A4Q27676519-12A92A68-1242-49DD-AE4C-6DD3A3F0AE75Q30558844-58D36096-9655-4F29-B714-AEB43783C0FDQ33584756-D6FA0D48-BF6D-448F-9262-57D72A8705D2Q33633277-13FF3FE7-3FBE-4D5B-B298-6C885EBADBB1Q34033280-6D0BCD72-3629-47B1-85FD-EE3F032746C1Q34261815-32C4F90D-27FE-48B8-9408-3723831CAC23Q34429367-1B275737-F5AD-45CE-803A-804266EE39C7Q34667746-2EA25F4E-F1A5-4CDF-9BE6-209D8BDEBEEFQ34791913-125E1453-3CC0-4A0D-B470-5717ACB79C40Q34992681-7410F460-8ADB-4948-8F27-44804D2190D2Q35017003-571F8BE3-AE74-4447-B67B-EC6E7DF293B6Q35078276-13BC7FEB-8A3E-4822-AF34-BEE296B6F9CFQ35126751-1C0DA48F-981C-4CF7-B064-ECC369BC9051Q35565769-30A80113-B8D5-411E-8EFE-43C3AE3224C0Q35618835-4755189F-DBD8-4C90-93F1-4297915A5182Q35658592-D5857E50-EDDF-4FE5-A1F2-2C584C4EC212Q35705983-16C1C58F-0630-4686-BB9A-ABFCE68167FAQ35826589-1FBA7019-5D1A-4A5B-8105-77950FB11A40Q36594178-9E74BCA6-864A-4CBD-9656-FD1C89939D9CQ36664240-C03C49C7-B9BA-49DB-8F83-25A66412F3A1Q36740254-48A0CD86-144D-4852-AA45-B5C2908E1079Q36759761-4BB39FF2-C727-4690-8C67-6959A2395E99Q36836468-F98FE122-E436-4ECA-A487-C8FD7FF88F94Q37328835-0391B818-C0DC-4D5F-9A73-ED9595CF60D6Q37508260-56612027-1702-43EA-81E6-EC1B52911F2FQ37627897-92C47574-D4CB-4142-AD09-A9A75886FD0CQ37676263-F2325CA4-C030-4641-AECD-94D6AA18A3CAQ37718852-F60D567F-6279-4AB2-9594-F18B1DFE737BQ37718861-5853C6DB-B995-4E10-AEF2-A9439B32E391Q37938886-3FA86889-A7E0-49E1-ACD3-3A3640668E15Q37974160-2136E884-3E79-4BF1-97BA-31A558AC193EQ38160538-F2950E79-4831-45E9-B957-7FC400096A7BQ38187126-CA32A686-F847-4B56-A217-5A141BA9198FQ38209337-24BC543E-5A8D-4F74-852F-F018DCB7E68DQ38295771-01F87DCD-4B13-4B2D-8821-9D59126BF5BEQ38618197-55BE867A-822B-492C-B24F-8E211367DD62Q38720608-EF7D4B88-9FE9-480D-9282-9D02502D0F8DQ38822813-441FC69D-B006-4335-BAE3-F61A512579B1
P2860
Advances and future challenges in adenoviral vector pharmacology and targeting.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Advances and future challenges in adenoviral vector pharmacology and targeting.
@en
Advances and future challenges in adenoviral vector pharmacology and targeting.
@nl
type
label
Advances and future challenges in adenoviral vector pharmacology and targeting.
@en
Advances and future challenges in adenoviral vector pharmacology and targeting.
@nl
prefLabel
Advances and future challenges in adenoviral vector pharmacology and targeting.
@en
Advances and future challenges in adenoviral vector pharmacology and targeting.
@nl
P2093
P2860
P921
P1433
P1476
Advances and future challenges in adenoviral vector pharmacology and targeting.
@en
P2093
Christopher Y Chen
Eric A Weaver
Michael A Barry
Reeti Khare
P2860
P304
P356
10.2174/156652311796150363
P407
P577
2011-08-01T00:00:00Z